Rapid Dose Therapeutics Corp.

Equities

DOSE

CA75339A1012

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange Other stock markets 02:05:57 2024-05-15 pm EDT			5-day change	1st Jan Change
0.23 ^CAD	+4.55%		+4.55%	+39.39%

Mar. 25	Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding	CI
Feb. 08	Rapid Dose Therapeutics Corp. Appoints Angela O'Leary to the Board of Directors	CI

Rapid Dose Therapeutics Corp. Appoints Rina Carlini as Vice President, Research & Innovation

June 06, 2019 at 07:00 am EDT

Rapid Dose Therapeutics Corp. announced that Dr. Rina Carlini has been appointed Vice President, Research & Innovation. Dr. Carlini is an accomplished scientist and management executive with 25 years of experience in technology innovation, product development, commercialization within the sectors of health technology, life science, IoT, artificial intelligence, advanced manufacturing, and nanotechnology. Rina's professional experience spans diverse industries and leadership roles, including pharma drug discovery R&D (Merck, Syntex), as Director of Nanotechnology for Xerox Innovation Group (Canada), Director of Commercialization at GreenCentre Canada, and President & CEO of Haltech Regional Innovation Centre.

Latest news about Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in funding	Mar. 24	CI
Rapid Dose Therapeutics Corp. Appoints Angela O'Leary to the Board of Directors	Feb. 08	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	Jan. 29	CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in funding	Jan. 18	CI
Rapid Dose Therapeutics Corp. announced that it has received CAD 3.134445 million in funding	Dec. 21	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-29	CI
Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of Directors	23-09-22	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 28, 2023	23-07-27	CI
Rapid Dose Therapeutics Narrows Fiscal Q4 Loss, Revenue Grows	23-06-29	MT
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	23-06-27	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Full Year Ended February 28, 2023	23-06-27	CI
Rapid Dose Increased Proposed Private Placement Financing of Up to $5 Million; Gained 30% on Tuesday	23-06-14	MT
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in funding	23-06-01	CI
Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian Market	23-05-10	CI
Rapid Dose Therapeutics Corp. Announces Changes to Its Board of Directors	23-04-14	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	23-01-30	CI
Rapid Dose Therapeutics Corp. Auditor Raises 'Going Concern' Doubt	23-01-26	CI
Rapid Dose Therapeutics Corp. Reports Earnings Results for the First Quarter Ended May 31, 2022	23-01-26	CI
Rapid Dose Therapeutics Brief: Says Co and its Auditors Continuing to work "diligently" to complete Audit of Annual financial statements for the fiscal year ended February 28, 2022	23-01-10	MT
Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order	22-12-30	MT
Rapid Dose Therapeutics Corp. Enters Supplier and Purchase Agreement with A Leading Gas and Convenience Store Retailer for Nutraceutical and Vitamin Products	22-09-23	CI
Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in funding	22-05-25	CI
Rapid Dose Therapeutics Corp. announced a financing transaction	22-05-24	CI
Rapid Dose Therapeutics Corp. Provides Shareholder Update Regarding Vaccine Collaboration Agreement with Oakland Health Limited in the United Kingdom	22-05-12	CI
Rapid Dose Therapeutics Corp. and Skycare Compounding Labs to Provide Patients with Novel Oral Delivery Option for Pharmaceutical Products	22-04-26	CI

Chart Rapid Dose Therapeutics Corp.

Duration

Period

More charts

Company Profile

Rapid Dose Therapeutics Corp. is a Canadian biotechnology company. The Company provides disruptive drug delivery technologies designed to improve patient outcomes. The Companyâs flagship product, QuickStrip, is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals, and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. It offers over-the-counter and pharmaceutical drug delivery solutions. Its QuickStrip Energy delivers energizing caffeine. Its QuickStrip B12 delivers vitamin B12 to the system, assisting with metabolism and physical energy. Its QuickStrip Sleep delivers melatonin to the system, inducing natural and healthy sleep. QuickStrip Lidocaine is its dental product. The Company also provides production and consultation to the nutraceutical, cannabis healthcare and pharmaceutical manufacturing industries.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-29 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Drug Delivery Systems

	1st Jan change	Capi.
RAPID DOSE THERAPEUTICS CORP.	+39.39%	19.47M
SEDANA MEDICAL AB	+0.82%	213M

Drug Delivery Systems